who shouldn't take glp 1 Many people remain excluded from GLP-1 clinical trials for weight loss Who Should NOT Take GLP-1

The PeptideKnow archive covers this in detail in the 503B GLP-1 compounding proposal explainer and in the 503B exclusion analysis

Planning your supply For a standard 20-week escalation from 2.5 mg to 15 mg: Weeks 1 to 8: one 30 mg vial (10 mg + 20 mg = 30 mg used) Weeks 9 to 12: one 30 mg vial (30 mg at 7.5 mg/week) Weeks 13 to 16: one 30 mg vial (30 mg at 10 mg/week, used in 3 weeks) Weeks 17 to 20: two 30 mg vials (60 mg at 12.5-15 mg/week) Total: approximately 4 to 5 vials for a 20-week protocol

However, among patients with T2DM, there was no association between GLP-1 RAs and new-onset cancers, such as pancreatic cancer, thyroid cancer, and MTC

Bibcode:1986JEMBE..96..225B

Tesamorelin under its FDA-approved indication may be covered in specific clinical scenarios, but coverage for wellness use is rarely approved